Sun Pharma Advanced Research Company Ltd.
Snapshot View

193.65 -1.20 ▼-0.6%

30 January 2023, 04:01:00 PM
Volume: 16,059

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sparc.life
Market Cap 6,247.04 Cr.
Enterprise Value(EV) 6,466.88 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) -7.32 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-09
Industry PE 32.78 Trailing Twelve Months Ending 2022-09
Book Value / Share -8.28 Trailing Twelve Months Ending 2022-09
Price to Book Value -23.24 Calculated using Price: 192.50
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 32.45 Cr. 324,521,588 Shares
FaceValue 1
Company Profile
The company is engaged in the pharmaceutical research and development. The company's core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS).

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-0.62%
1 Week
-4.58%
1 Month
-7.26%
3 Month
-23.02%
6 Month
-15.86%
1 Year
-38.34%
2 Year
+8.31%
5 Year
-58.43%
10 Year
+79.86%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 24.62 -33.17 -109.16 -127.40 -156.84 -74.72 -225.08
Return on Capital Employed (%) 24.02 -31.74 -71.37 -94.66 -113.05 -59.95 -178.95 -254.10 -225.57
Return on Assets (%) 15.29 -23.65 -44.68 -53.72 -66.85 -40.89 -93.11 -60.18 -79.80

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 139 100 32 158 185 296 -19 -168 31 -119
Non Curr. Liab. 9 10 10 10 12 7 56 165 77 82
Curr. Liab. 39 37 125 108 116 95 235 233 171 329
Minority Int.
Equity & Liab. 188 147 167 277 313 398 273 230 280 292
Non Curr. Assets 77 83 99 118 138 141 205 167 209 219
Curr. Assets 110 63 67 158 175 257 67 63 71 73
Misc. Exp. not W/O 1 0 1
Total Assets 188 147 167 277 313 398 273 230 280 292

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 167 156 161 181 78 183 77 253 137 147
Other Income 10 3 3 14 5 14 10 5 7 1
Total Income 177 159 164 195 83 196 87 258 144 148
Total Expenditure -134 -191 -224 -304 -321 -334 -387 -388 -324 -366
PBIDT 43 -32 -60 -109 -238 -138 -300 -130 -180 -218
Interest -6 0 -2 -2 0 0 -3 -11 -13 -9
Depreciation -4 -7 -8 -8 -8 -8 -9 -11 -10 -11
Taxation -4
Exceptional Items 49
PAT 30 -40 -70 -119 -197 -145 -312 -151 -203 -238
Adjusted EPS 1 -2 -3 -5 -8 -6 -12 -6 -7 -9

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. -95 37 -41 -44 -128 -183 -172 -211 -152 -208
Cash Fr. Inv. -99 44 53 -13 -7 -105 -102 155 2 -29
Cash Fr. Finan. 194 -81 -1 51 194 224 274 55 159 229
Net Change 0 0 11 -7 60 -63 0 9 -8
Cash & Cash Eqvt 0 0 11 4 64 0 0 0 9 1

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 68.46 68.46 68.46 68.10 68.10 69.09 69.09 69.09 65.67
Public 31.54 31.54 31.54 31.90 31.90 30.91 30.91 30.91 34.33
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.75 2.29 2.29 2.29 2.29 2.18 2.18 1.65 0.90

Announcements View Details >>

Fri, 27 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate by the holder
Wed, 25 Jan 2023
"Launch Of SEZABY (Phenobarbital Sodium Powder For Injection) In The U.S. For The Treatment Of Neonatal Seizures".
We would like to inform that the Company has received an intimation from the partner about the launch of SEZABY (phenobarbital sodium powder for injection) in the U.S. for the treatment of neonatal seizures. The Company is eligible to receive US$ 5 million as milestone payment upon commercialization of SEZABY the first and only product approved in U.S. for the treatment of neonatal seizures in term and preterm infants.Pursuant to the agreement between the parties SPARC shall also be eligible for future milestones and royalties on net sales.
Fri, 20 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate by the holder

Technical Scans View Details >>

Mon, 30 Jan 2023
Higher Delivery Quantity Higher Delivery Quantity
Close Crossing Last Week Low Close Crossing Last Week Low
Closing Below Previous Low Closing Below Previous Low
Closing Below Previous Low for 3 days Closing Below Previous Low for 3 days
Making Lower Lows for 3 days Making Lower Lows for 3 days

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 252,338.06 1,051.70 +0.8%
Divi's Laboratories Ltd. 89,367.34 3,366.40 -0.6%
Cipla Ltd. 83,741.18 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. 72,084.75 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. 61,094.10 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. 52,291.51 1,545.05 +0.5%
Abbott India Ltd. 44,555.01 20,967.75 -1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 61.43 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-09 29.89 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-12 31.74 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.79 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.76 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.93 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-09 50.53 20,967.75 -1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.75 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-09 7.37 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-12 3.69 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.28 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.21 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.20 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-09 16.41 20,967.75 -1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 0.04 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 0.00 20,967.75 -1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 29.95 20,967.75 -1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 29.95 20,967.75 -1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,967.75 -1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 798.70 20,967.75 -1.2%

FAQ's On Sun Pharma Advanced Research Company Ltd.

What is Sun Pharma Adv. Res share price?

Can I buy Sun Pharma Adv. Res shares now?

What is the Market Cap of Sun Pharma Adv. Res?

What is the 52 Week High and Low of Sun Pharma Adv. Res?

What is the trend of Sun Pharma Adv. Res share price?